Ziegler Louise, Hedin Ulf, Gottsäter Anders
Division of Internal Medicine, Department of Clinical Sciences, Karolinska Institute, Danderyd Hospital Stockholm, Sweden.
Vascular Surgery Division, Department of Molecular Medicine and Surgery, Karolinska Institute Stockholm, Sweden.
Eur Cardiol. 2022 Mar 23;17:e09. doi: 10.15420/ecr.2021.58. eCollection 2022 Feb.
Lower extremity artery disease (LEAD), a chronic condition with disturbed lower extremity circulation due to narrowing of the arteries, is predominantly caused by atherosclerosis and is associated with the presence of cardiovascular risk factors and an increased risk of cardiovascular events. LEAD is prevalent among older individuals and predicted to rise with the ageing population. In progressive disease, the patient experiences symptoms of ischaemia when walking and, in advanced critical limb-threatening ischaemia, even at rest. However, LEAD is asymptomatic in most patients, delaying diagnosis and treatment. In this setting, circulating biomarkers may facilitate earlier diagnosis in selected individuals. This review provides a broad overview of the circulating biomarkers investigated to date in relation to LEAD and discusses their usefulness in clinical practice.
下肢动脉疾病(LEAD)是一种由于动脉狭窄导致下肢血液循环紊乱的慢性疾病,主要由动脉粥样硬化引起,并与心血管危险因素的存在以及心血管事件风险增加相关。LEAD在老年人中普遍存在,且预计会随着人口老龄化而增加。在疾病进展过程中,患者行走时会出现缺血症状,在晚期严重肢体缺血性疾病中,甚至在休息时也会出现症状。然而,大多数LEAD患者没有症状,从而延误了诊断和治疗。在这种情况下,循环生物标志物可能有助于在特定个体中更早地进行诊断。本综述广泛概述了迄今为止研究的与LEAD相关的循环生物标志物,并讨论了它们在临床实践中的实用性。